Finimize - 🚗 Toyota's breaking down

Hi Reader, here's what you need to know for November 2nd in 3:14 minutes.

💸 Want to make smarter investment decisions? Now you can develop your financial know-how with 6 months of free Finimize Premium, and unlock ultimate financial power with 3 months of free Revolut Premium too. We’ll even give you £10 (or equivalent) just for signing up.

Get it all for free today

Today's big stories

Johnson & Johnson is buying heart device maker Abiomed in its biggest deal in almost six years
Here’s where Blackstone sees three big risks for the global economy, and the biggest opportunities – Read Now
Toyota reported disappointing quarterly results, and even the falling yen couldn't help

Finger On The Pulse

What’s Going On Here?

Healthcare giant Johnson & Johnson (J&J) announced on Tuesday that it’s buying heart device maker Abiomed.

What Does This Mean?

J&J announced plans to spin off its consumer goods division at the end of last year, going all-in on its other business areas instead. And now that it’s buying Abiomed in a deal worth around $17 billion, it seems to be putting its money where its mouth is. This deal – set to be J&J’s biggest in nearly six years – will cost a pretty penny: the healthcare titan’s shelling out 51% more than Abiomed’s shares were worth before the deal was announced. For J&J, it seems to be a case of “you get what you pay for”: this deal will let it get its mitts on Abiomed’s renowned Impella heart pumps for patients with severe heart disease, famed for being the smallest in the world, and inject its medical device segment with the tidy $1 billion a year that Abiomed currently brings in.

Why Should I Care?

For markets: Heart’s in the right place.
2022’s been a slow year for mergers and acquisitions, but this bumper deal bucks the trend. After all, J&J’s flush with cash from vaccine sales right now, so it can afford to snap up firms while valuations are low. And this isn’t just a smart short-term grab: heart disease is already one of the world’s leading causes of death, and with a growing population, demand for Abiomed’s devices is only likely to increase.

The bigger picture: Viva diversification.
J&J’s scouting out new opportunities as Covid slips away, and there are signs competitors are following suit. Rival medical goliath Pfizer reported impressive results on Tuesday, but with vaccine demand slowing outside the US, it’s certainly not putting all its eggs in one basket: it just announced plans to launch 19 new products over the next 18 months.

You might also like: The big opportunities behind big pharmaceutical companies.

Copy to share story: https://go.finimize.com/wp/news/finger-on-the-pulse/

🙋 Ask a question

Analyst Take

Here’s Where Blackstone Sees Opportunities Now

By Russell Burns, Analyst

Blackstone’s latest overview of the global economy doesn’t make for cheerful reading.

Quite the opposite: the way the investment house sees things, there are three massive threats facing the world’s economies.

But Blackstone still believes there are opportunities to be found – and I won’t make you work to find out where they are.

So that’s today’s Insight: where Blackstone sees risks for the economy, and where you can find the best opportunities hiding.

Read or listen to the Insight here

Finimize x Revolut

Pretty good stuff, right? Our analysts write Insights like this every day, and you can read every single one of them with Finimize Premium.

There’s no better time to get started: our new partnership means you can get six free months of Finimize Premium and three free months of Revolut Premium if you sign up for Revolut today.

We’ll even send you £10 (or equivalent) to your Revolut account to get you started.

Upgrade your trading experience

Picture a professional trader’s setup: two coffees, four monitors, and all the tools in the world.

No wonder they’re always the first to spot the next big trade: pro-level tools like heat maps, stock comparison metrics, earnings alerts, and technical indicators sure make a difference.

Well, moomoo can get you all – okay, bar the monitors – of those swanky features, so you can trade like the pros from the comfort of your home. Or your mobile, even, if you’re on the move.

So with just a couple taps, you can compare stocks using hundreds of different metrics, keep tabs on earnings calls, and assess industrial chains around the world. And that’s only the start.

It’s just a shame the coffees aren’t included. Discover what moomoo can do today.

Find Out More

Disclaimer

Level 2 data is free to moomoo users that have an approved brokerage account with Moomoo Financial Inc. Terms and Conditions apply; please visit https://www.moomoo.com/support/topic490 for details. $2,000 value is based on the market price at the time of the gift. Moomoo is a financial information and trading app offered by Moomoo Techonologies Inc. In the U.S., investment products and services on Moomoo are offered by Moomoo Financial Inc., Member FINRA/SIPC. Any illustrations, scenarios, or specific securities referenced herein are strictly for illustrative purposes. Past investment performance does not guarantee future results. Investing involves risk and the potential to lose principal.

Fall Time

What’s Going On Here?

Toyota reported disappointing quarterly results on Tuesday, putting an end to the world’s biggest carmaker’s rousing pandemic performance.

What Does This Mean?

Toyota handled supply chain hiccups better than most carmakers during the pandemic, and even managed to pull record profit out of the last bumpy financial year. But it looks like chips are its Achilles heel now: chipmakers have prioritized supplying chips for electronics companies, with Toyota’s less-profitable auto chips falling by the wayside. And while the weaker yen gave the Japanese carmaker a leg up when it converted its international profit back into its home currency, exorbitant material costs more than wiped out that benefit.

So at the end of the day (well, the last quarter), Toyota’s operating profit dropped a much worse-than-expected 25% from the same time last year, marking its fourth-straight fall. And while Toyota reported an uptick in its production, the carmaker said that was unsustainable: it slashed this year’s production target from 9.7 million to 9.2 million.

Why Should I Care?

For markets: Green-eyed investors.
Not even the announcement of a $1-billion buyback program could stop investors from sending Toyota’s stock down after that news. That’s not the end of its worries either: once the eco-friendly drivers’ darling thanks to its hybrid models, increasingly green-minded investors have criticized the carmaker’s slow embrace of fully electric vehicles. That could be why Toyota’s considering revamping its $38-billion EV plan after just one year – well, and the fact it had to recall its first mass-produced all-electric vehicle over safety worries this year.

The bigger picture: Low and behold.
The yen fell to a 32-year low against the dollar last month, and Japan’s been trying to buoy it up by buying yen and selling dollars – all while maintaining its currency-squashing ultra-low interest rates. Data out this week showed Japan spent a record $43 billion on that technique last month, and it can afford to keep that going: Japan holds the world’s second-biggest foreign currency reserves after China.

You might also like: Japan’s been spending billions to slow the yen’s slide. It’s not working.

Copy to share story: https://go.finimize.com/wp/news/fall-time/

🙋 Ask a question

💬 Quote of the day

“We don’t believe in rheumatism and true love until after the first attack.”

– Marie von Ebner-Eschenbach (an Austrian writer)

Tweet this

Your brand could represent the new investing era

The second Finimize Modern Investor Summit will celebrate the new era of investing.

So if your brand or product is helping to create the next generation of investing opportunities, our summit is the ideal place to showcase your potential.

Feature your product during speaker slots, fireside chats, and expert Q&A panels, and you’ll be able to directly engage with an engaged audience and demonstrate your brand’s true power.

Thousands of retail investors attended the Modern Investor Summit last year, so don’t miss your chance to get your product in front of our community this December.

Put your brand in the spotlight.

Find Out More

🌍 Finimize Live

🥳 Coming Up This Week…

All events in UK time.

🤑 Asset Allocation For Young Investors: 5pm, November 2nd
🙋‍♀️ Ladies Investing Club Meet Up: 6.30pm, November 2nd (in person)
😎 How To Build A Portfolio Ready For The Next Decade: 1pm, November 3rd

👀 And After That…

💰 Strategies For Market Volatility: 1pm, November 8th
✨ How To Profit From Special Situations As A Value Investor: 5pm, November 9th
🔧 Tools Value Investors Use For Turbulent Times: 6pm, November 10th
🔥 How To Build Better Financial Habits In Your 20s & 30s: 3pm, November 11th
♻️ How To Build An Eco Friendly Crypto Portfolio: 1pm, November 14th
💥 How To Diversify During High Inflation: 6pm, November 14th
🐻 How To Survive A Crypto Bear Market: 7pm, November 15th
✅ How To Successfully Invest In Dividend Stocks: 6pm, November 22nd
🚀 2023 Outlook: What’s Next For Crypto?: 6.30pm, November 23rd (in-person, London)
🌍 Finding Opportunities In A Challenging Market With BlackRock: 1pm, December 2nd
🎉 Modern Investor Summit: 12pm, December 6th & 7th

🎯 On Our Radar

Almond moms. Youth trends for out-of-touch adults.
Off kilter. The living things that shatter the world’s symmetry.
Cures for the chronically online. Sign out, shut down, touch grass.
Crime Scene Inspiration. How one TikTok “layabout” landed a TV slot.
Buongiorno, Sicily. Where to stay on one of Italy’s most beautiful islands.

❤️ Share with a friend

Your Referrals: 0

Thanks for reading Reader. If you liked today's brief, we'd love for you to share it with a friend.

Share your unique link:

https://finimize.com/invite/?kid=177ZWC

You stay classy, Reader 😉

We’d love to hear your thoughts. Give feedback

Want to advertise with us too? Get in touch

Image Credits:

Image credits: Drp8 - Shutterstock | Winning7799 - Shutterstock

Preferences:

Update your email or change preferences

View in browser

Unsubscribe from all Finimize Emails

😴

Crafted by Finimize Ltd. | Bow Bells House, Bread Street, London, EC4M 9HH

All content provided by Finimize Ltd. is for informational and educational purposes only and is not meant to represent trade or investment recommendations. You signed up to this mailing list at finimize.com or through one of our partners. © Finimize 2021

Rival medical goliath Pfizer medical device segment consumer goods division other business areas smart shortterm grab three massive threats RevolutPretty good stuff ultimate financial power big pharmaceutical companies heart device maker disappointing quarterly results Impella heart pumps stock comparison metrics smarter investment decisions next big trade severe heart disease three free months Moomoo Techonologies Inc free Finimize Premium three big risks free Revolut Premium Moomoo Financial Inc six free months Healthcare giant Johnson

Finimize - 🚗 Toyota's breaking down

Today's big stories

Finger On The Pulse

What’s Going On Here?

What Does This Mean?

Why Should I Care?

Here’s Where Blackstone Sees Opportunities Now

Upgrade your trading experience

Fall Time

What’s Going On Here?

What Does This Mean?

Why Should I Care?

Your brand could represent the new investing era

🥳 Coming Up This Week…

👀 And After That…

Key phrases

Older messages

⛏ Tesla's digging for gold

⛏ Tesla's digging for gold

💰 Big Oil's just bragging at this point

📉 Apple and Amazon's big results are in

📉 Meta's dropping off

You Might Also Like

Home makeover on a budget? We have just the thing.

Mother Earth 🤝 Jane Fonda

Visionary Valuations - Issue #464

Prepare for a Recession Unlike Any Other

Three facts about the rising number of UK business exits

Big Tech drops

📉 ASML's chips are down

Are you having credit report trouble?

What’s the right retirement age? Experts say it depends.

Using my credit card for cash — it's a bad idea, right?